BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 33019612)

  • 1. Germline BRCA Mutation and Clinical Outcomes in Breast Cancer Patients Focusing on Survival and Failure Patterns: A Long-Term Follow-Up Study of Koreans.
    Kim H; Choi DH; Park W
    Medicina (Kaunas); 2020 Oct; 56(10):. PubMed ID: 33019612
    [No Abstract]   [Full Text] [Related]  

  • 2. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study.
    Copson ER; Maishman TC; Tapper WJ; Cutress RI; Greville-Heygate S; Altman DG; Eccles B; Gerty S; Durcan LT; Jones L; Evans DG; Thompson AM; Pharoah P; Easton DF; Dunning AM; Hanby A; Lakhani S; Eeles R; Gilbert FJ; Hamed H; Hodgson S; Simmonds P; Stanton L; Eccles DM
    Lancet Oncol; 2018 Feb; 19(2):169-180. PubMed ID: 29337092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy.
    Kirova YM; Stoppa-Lyonnet D; Savignoni A; Sigal-Zafrani B; Fabre N; Fourquet A;
    Eur J Cancer; 2005 Oct; 41(15):2304-11. PubMed ID: 16140006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Twenty-one-gene recurrence score assay in BRCA-associated versus sporadic breast cancers: Differences based on germline mutation status.
    Shah PD; Patil S; Dickler MN; Offit K; Hudis CA; Robson ME
    Cancer; 2016 Apr; 122(8):1178-84. PubMed ID: 26859126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations.
    Robson M; Levin D; Federici M; Satagopan J; Bogolminy F; Heerdt A; Borgen P; McCormick B; Hudis C; Norton L; Boyd J; Offit K
    J Natl Cancer Inst; 1999 Dec; 91(24):2112-7. PubMed ID: 10601383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes and risk of subsequent breast events in breast-conserving surgery patients with BRCA1 and BRCA2 mutation.
    Ye F; Huang L; Lang G; Hu X; Di G; Shao Z; Cao A
    Cancer Med; 2020 Mar; 9(5):1903-1910. PubMed ID: 31912664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased risk of contralateral breast cancer for BRCA1/2 wild-type, high-risk Korean breast cancer patients: a retrospective cohort study.
    Kang E; Jung JJ; Lim C; Kim HK; Lee HB; Han W; Moon HG
    Breast Cancer Res; 2024 Jan; 26(1):14. PubMed ID: 38254240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Germline breast cancer susceptibility gene mutations and breast cancer outcomes.
    Wang YA; Jian JW; Hung CF; Peng HP; Yang CF; Cheng HS; Yang AS
    BMC Cancer; 2018 Mar; 18(1):315. PubMed ID: 29566657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of breast surgical procedure on survival in BRCA mutated patients with invasive breast cancer: Mastectomy versus conservative treatment.
    Mahiou K; Jankowski C; Vincent L; Costaz H; Padeano MM; Mamguem A; Dabakuyo S; Coutant C
    J Gynecol Obstet Hum Reprod; 2024 May; 53(5):102760. PubMed ID: 38428460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of BRCA germline mutations on breast cancer prognosis: A systematic review and meta-analysis.
    Baretta Z; Mocellin S; Goldin E; Olopade OI; Huo D
    Medicine (Baltimore); 2016 Oct; 95(40):e4975. PubMed ID: 27749552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
    Franceschini G; Di Leone A; Terribile D; Sanchez MA; Masetti R
    Ann Ital Chir; 2019; 90():1-2. PubMed ID: 30872561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pregnancy After Breast Cancer in Patients With Germline
    Lambertini M; Ameye L; Hamy AS; Zingarello A; Poorvu PD; Carrasco E; Grinshpun A; Han S; Rousset-Jablonski C; Ferrari A; Paluch-Shimon S; Cortesi L; Senechal C; Miolo G; Pogoda K; Pérez-Fidalgo JA; De Marchis L; Ponzone R; Livraghi L; Estevez-Diz MDP; Villarreal-Garza C; Dieci MV; Clatot F; Berlière M; Graffeo R; Teixeira L; Córdoba O; Sonnenblick A; Luna Pais H; Ignatiadis M; Paesmans M; Partridge AH; Caron O; Saule C; Del Mastro L; Peccatori FA; Azim HA
    J Clin Oncol; 2020 Sep; 38(26):3012-3023. PubMed ID: 32673153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study.
    Kauff ND; Domchek SM; Friebel TM; Robson ME; Lee J; Garber JE; Isaacs C; Evans DG; Lynch H; Eeles RA; Neuhausen SL; Daly MB; Matloff E; Blum JL; Sabbatini P; Barakat RR; Hudis C; Norton L; Offit K; Rebbeck TR
    J Clin Oncol; 2008 Mar; 26(8):1331-7. PubMed ID: 18268356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcomes of female breast cancer according to BRCA mutation status.
    Cronin-Fenton DP; Kjærsgaard A; Nørgaard M; Pedersen IS; Thomassen M; Kaye JA; Gutierrez L; Telford C; Lewis J; Tyczynski JE; Sørensen HT
    Cancer Epidemiol; 2017 Aug; 49():128-137. PubMed ID: 28601786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biologic behavior of resected BRCA-mutated pancreatic cancer: Comparison with sporadic pancreatic cancer and other BRCA-related cancers.
    Kim SH; Hwang HK; Lee WJ; Kang CM
    Pancreatology; 2021 Apr; 21(3):544-549. PubMed ID: 33612442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of BRCA Mutation Status on Survival of Women With Triple-negative Breast Cancer.
    Yadav S; Ladkany R; Yadav D; Alhalabi O; Khaddam S; Isaac D; Cardenas PY; Zakalik D
    Clin Breast Cancer; 2018 Oct; 18(5):e1229-e1235. PubMed ID: 29402697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Higher antitumor activity of trabectedin in germline BRCA2 carriers with advanced breast cancer as compared to BRCA1 carriers: A subset analysis of a dedicated phase II trial.
    Ghouadni A; Delaloge S; Lardelli P; Kahatt C; Byrski T; Blum JL; Gonçalves A; Campone M; Nieto A; Alfaro V; Cullell-Young M; Lubinski J
    Breast; 2017 Aug; 34():18-23. PubMed ID: 28467918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer.
    Gonzalez-Angulo AM; Timms KM; Liu S; Chen H; Litton JK; Potter J; Lanchbury JS; Stemke-Hale K; Hennessy BT; Arun BK; Hortobagyi GN; Do KA; Mills GB; Meric-Bernstam F
    Clin Cancer Res; 2011 Mar; 17(5):1082-9. PubMed ID: 21233401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer.
    Yang D; Khan S; Sun Y; Hess K; Shmulevich I; Sood AK; Zhang W
    JAMA; 2011 Oct; 306(14):1557-65. PubMed ID: 21990299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and molecular characterization of BRCA-associated breast cancer: results from the DBCG.
    Soenderstrup IMH; Laenkholm AV; Jensen MB; Eriksen JO; Gerdes AM; Hansen TVO; Kruse TA; Larsen MJ; Pedersen IS; Rossing M; Thomassen M; Ejlertsen B
    Acta Oncol; 2018 Jan; 57(1):95-101. PubMed ID: 29164974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.